Business review P06P53 Governance and remuneration P54P90 Financial statements P91P182 Shareholder information P183P204 81 Remuneration Report Mr Witty and Mr Heslop also contribute 125 per month to buy in the case of outstanding awards under the GlaxoSmithKline shares under the ShareReward plan.
The company matches the Annual Investment Plan which was closed to new deferrals number of shares bought each month.
with effect from the first quarter of 2006 provided that their agreement is terminated other than for cause, any deferred The Executives also receive other benefits including healthcare amount, and any income and gains, are automatically medical and dental, personal financial advice and life assurance.
distributed as soon as administratively practicable after The cash value of the benefits received by the Executive Directors termination.
in 2009 is shown on page 83. in line with the policy applicable to US senior executives, Executive Director terms and conditions Dr Slaoui may become eligible, at a future date, to receive Executive Director contracts continuing medical and dental insurance after retirement.
The policy set out below provides the framework for contracts for Following the merger, those participants in the legacy share Executive Directors.
option schemes who elected to exchange their legacy options for options over GlaxoSmithKline shares will receive an additional cash Notice period on 12 calendar months benefit equal to 10% of the grant price of the original option.
termination by the This additional benefit is triggered when the option is exercised or employing company or lapses.
To qualify for this additional cash benefit, participants had executive to retain their options until at least the second anniversary of the Termination payment 1 x annual salary effective date of the merger.
1 x annual on-target bonus Outside appointments for Executive Directors No mitigation required Any outside appointments must be approved by the Chairman on Vesting of LTIs Rules of relevant incentive plan, as behalf of the Board.
It is the companys policy that remuneration approved by shareholders earned from such appointments may be kept by the individual Executive Director.
Pension Based on existing arrangements and terms of the relevant pension plan Non-Executive Director terms and conditions Non-Executive Directors of GlaxoSmithKline do not have service Non-compete clause 12 months from termination contracts but instead have letters of appointment under which it notice date is agreed that they serve the company as a Non-Executive Director until the conclusion of the AGM following the third anniversary of The CEO has agreed an amendment to his contract to remove a contractual entitlement to bonus as part of his termination package.
The contracts of their appointment.
In each case this can be extended for a further new Executives will not normally include a bonus element in any termination term of three years by mutual agreement.
However, to the extent that the company imposes non-compete term longer than three years without offering themselves for reprovisions and restricts the individual from working elsewhere, a compensatory election by the shareholders.
Non-Executive Directors are not entitled to compensation if their The ability to impose a 12-month non-compete period and a non-solicitation appointment is terminated.
restriction on an Executive is considered important by the company in order to have the ability to protect the Groups intellectual property and staff.
In light The following table shows the date of the initial letter of of this, the Committee believes that it would not be appropriate to provide for appointment of each Non-Executive Director: mitigation in the contracts.
Non-Executive Director Date of letter of appointment The following table sets out the details of the Executive Directors service contracts: Professor Sir Roy Anderson 28.09.07 Current Directors Date of contract Effective date Expiry date Dr S Burns 12.02.07 Mr L Culp 09.06.03 Mr A Witty 18.06.08 22.05.08 31.08.24 Sir Crispin Davis 09.06.03 Mr J Heslop 16.03.05 01.04.05 31.01.14 Sir Deryck Maughan 26.05.04 Dr M Slaoui 16.05.06 01.06.06 01.08.19 Mr J Murdoch 26.02.09 Dr D Podolsky 03.07.06 Mr Wittys contract was renewed in June 2008 following his appointment as CEO, and was supplemented on 4th February 2010 to reflect the changes to his Mr T fide Swaan 21.12.05 severance terms outlined above.
Sir Robert Wilson 09.06.03 Sir Ian Prosser 19.06.00 No termination payments will be made in respect of any part of a Dr R Schmitz 19.06.00 notice period extending beyond the contract expiry date.
Other entitlements Sir Ian Prosser and Dr Ronaldo Schmitz retired from the Board at the conclusion of the AGM on 20th May 2009.
In addition to the contractual provisions outlined above, in the event that Executive Directors service agreements are terminated by their employing company, the following will apply: GSK Annual Report 2009
